Jocelyne Andre
Paris, 75010, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma.
Journal: Cancers
Published: February 26, 2020
TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
Journal: Oncotarget
Published: March 18, 2016
PARKIN Inactivation Links Parkinson's Disease to Melanoma.
Journal: Journal of the National Cancer Institute
Published: February 11, 2015
RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.
Journal: Oncotarget
Published: February 10, 2015
Driver KIT mutations in melanoma cluster in four hotspots.
Journal: Melanoma research
Published: October 12, 2014
Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
Journal: Human pathology
Published: September 20, 2012
Genetic variation at KIT locus may predispose to melanoma.
Journal: Pigment cell & melanoma research
Published: March 27, 2012
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 19, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026